PE20010700A1 - Compuestos de bencilaminopiperidina sustituidos - Google Patents
Compuestos de bencilaminopiperidina sustituidosInfo
- Publication number
- PE20010700A1 PE20010700A1 PE2001000276A PE0002762001A PE20010700A1 PE 20010700 A1 PE20010700 A1 PE 20010700A1 PE 2001000276 A PE2001000276 A PE 2001000276A PE 0002762001 A PE0002762001 A PE 0002762001A PE 20010700 A1 PE20010700 A1 PE 20010700A1
- Authority
- PE
- Peru
- Prior art keywords
- amino
- phenylpiperidine
- benzyl
- sunburns
- trifluoromethyl
- Prior art date
Links
- QACOELYINOMVBY-UHFFFAOYSA-N n-benzylpiperidin-1-amine Chemical class C=1C=CC=CC=1CNN1CCCCC1 QACOELYINOMVBY-UHFFFAOYSA-N 0.000 title 1
- 206010042496 Sunburn Diseases 0.000 abstract 4
- XQDSIGDVDWFZPP-UHFFFAOYSA-N 2-phenylpiperidin-1-amine Chemical compound NN1CCCCC1C1=CC=CC=C1 XQDSIGDVDWFZPP-UHFFFAOYSA-N 0.000 abstract 3
- VXNQJPMCJMJOMN-UHFFFAOYSA-N 1,1-difluoroethane Chemical class C[C](F)F VXNQJPMCJMJOMN-UHFFFAOYSA-N 0.000 abstract 2
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical class [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 abstract 2
- YKNINAKQXAPIKV-ROUUACIJSA-N (2s,3s)-n-[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-2-phenylpiperidin-3-amine Chemical compound FC1=CC=C(C(F)(F)F)C=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)NCCC1 YKNINAKQXAPIKV-ROUUACIJSA-N 0.000 abstract 1
- HYYFWRBWFTVCAE-HKUYNNGSSA-N (2s,3s)-n-[[2-methoxy-5-(1,1,2,2,2-pentafluoroethyl)phenyl]methyl]-2-phenylpiperidin-3-amine Chemical compound COC1=CC=C(C(F)(F)C(F)(F)F)C=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)NCCC1 HYYFWRBWFTVCAE-HKUYNNGSSA-N 0.000 abstract 1
- LAFDGMMACYWPSJ-UPVQGACJSA-N (2s,3s)-n-[[2-phenoxy-5-(trifluoromethyl)phenyl]methyl]-2-phenylpiperidin-3-amine Chemical compound N([C@@H]1[C@@H](NCCC1)C=1C=CC=CC=1)CC1=CC(C(F)(F)F)=CC=C1OC1=CC=CC=C1 LAFDGMMACYWPSJ-UPVQGACJSA-N 0.000 abstract 1
- -1 1,2,2,2-TETRAFLUORO-1- (TRIFLUOROMETHYL) ETHYL Chemical class 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- LAPWCYPRCPBMGJ-UHFFFAOYSA-N phenylmethanamine;piperidine Chemical class C1CCNCC1.NCC1=CC=CC=C1 LAPWCYPRCPBMGJ-UHFFFAOYSA-N 0.000 abstract 1
- LWMPFIOTEAXAGV-UHFFFAOYSA-N piperidin-1-amine Chemical compound NN1CCCCC1 LWMPFIOTEAXAGV-UHFFFAOYSA-N 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A LOS COMPUESTOS BENCILAMINO-PIPERIDINA SUSTITUIDOS DE PREFERENCIA (2S,3S)-3-(2-FLUORO-5-(TRIFLUOROMETIL)BENCIL)AMINO-2-FENILPIPERIDINA, (2S,3S)-3-(2-CLORO-5-(TRIFLUOROMETIL)BENCIL)AMINO-2-FENILPIPERIDINA, (2S,3S)-3-(2-FENOXI-5-(TRIFLUOROMETIL)-BENCIL)AMINO-2-FENILPIPERIDINA, (2S,3S)-2-FENIL-3-(5-(1,2,2,2-TETRAFLUORO-1-(TRIFLUOROMETIL)ETIL)-2-METOXIBENCIL)AMINOPIPERIDINA, (2S,3S)-3-(5-(1,1-DIFLUOROETIL)-2-(TRIFLUOROMETOXI)BENCIL)AMINO-2-FENILPIPERIDINA, (2S,3S)-3-(5-(1,1-DIFLUOROETIL)-2-METOXIBENCIL)AMINO-2-FENILPIPERIDINA; (2S,3S)-3-(2-METOXI-5-(1,1,2,2,2-PENTAFLUOROETIL)BENCIL)AMINO-2-FENILPIPERIDINA; (2S,3S)-3-(2-METOXI-5-(2,2,2-TRIFLUORO-1-HIDROXI-1-(TRIFLUOROMETIL)ETIL)-BENCIL)AMINO-2-FENILPIPERIDINA. LOS COMPUESTOS SON ANTAGONISTAS DE LA SUSTANCIA P Y PUEDE SER UTIL PARA EL TRATAMIENTO DE TRASTORNOS GASTROINTESTINALES, TRASTORNOS DEL SNC, ENFERMEDAD INFLAMATORIA, EMESIS, INCONTINENCIA URINARIA, DOLOR, MIGRANA, QUEMADURAS SOLARES, ENFERMEDADES O TRASTORNOS CAUSADOS POR HELICOBACTER PYLORI
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB9500683 | 1995-08-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010700A1 true PE20010700A1 (es) | 2001-07-09 |
Family
ID=11004362
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000276A PE20010700A1 (es) | 1995-08-24 | 1996-08-21 | Compuestos de bencilaminopiperidina sustituidos |
| PE1996000625A PE1398A1 (es) | 1995-08-24 | 1996-08-21 | Compuestos de bencilaminopiperidina sustituidos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1996000625A PE1398A1 (es) | 1995-08-24 | 1996-08-21 | Compuestos de bencilaminopiperidina sustituidos |
Country Status (42)
| Country | Link |
|---|---|
| US (1) | US6506775B1 (es) |
| EP (2) | EP1114817B1 (es) |
| JP (1) | JP3084069B2 (es) |
| KR (1) | KR100288673B1 (es) |
| CN (1) | CN1153764C (es) |
| AP (1) | AP643A (es) |
| AR (1) | AR006305A1 (es) |
| AT (2) | ATE258166T1 (es) |
| AU (1) | AU702698B2 (es) |
| BG (1) | BG64126B1 (es) |
| BR (1) | BR9609989A (es) |
| CA (1) | CA2227814C (es) |
| CO (1) | CO4480738A1 (es) |
| CZ (1) | CZ297543B6 (es) |
| DE (2) | DE69616817T2 (es) |
| DK (2) | DK0861235T3 (es) |
| DZ (1) | DZ2086A1 (es) |
| ES (2) | ES2163017T3 (es) |
| HK (1) | HK1014935A1 (es) |
| HR (1) | HRP960386B1 (es) |
| HU (1) | HU225480B1 (es) |
| IL (1) | IL119078A (es) |
| IS (1) | IS1947B (es) |
| MA (1) | MA23961A1 (es) |
| MX (1) | MX9801467A (es) |
| MY (1) | MY114800A (es) |
| NO (1) | NO310720B1 (es) |
| NZ (1) | NZ308207A (es) |
| OA (1) | OA10666A (es) |
| PE (2) | PE20010700A1 (es) |
| PL (1) | PL186773B1 (es) |
| PT (2) | PT861235E (es) |
| RO (1) | RO119299B1 (es) |
| RU (1) | RU2152930C2 (es) |
| SI (2) | SI1114817T1 (es) |
| SK (1) | SK282925B6 (es) |
| TN (1) | TNSN96107A1 (es) |
| TR (1) | TR199800300T1 (es) |
| TW (1) | TW340842B (es) |
| UA (1) | UA48981C2 (es) |
| WO (1) | WO1997008144A1 (es) |
| YU (1) | YU49122B (es) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9706196A (es) * | 1996-08-14 | 1998-02-28 | Pfizer | Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p. |
| TW426667B (en) * | 1997-11-19 | 2001-03-21 | Pfizer | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists |
| US6777428B1 (en) | 1999-02-10 | 2004-08-17 | Eli Lilly And Company | 5-HT1f agonist |
| NZ514697A (en) * | 1999-05-06 | 2004-04-30 | Pfizer Prod Inc | Substituted benzolactam compounds |
| RS49964B (sr) | 1999-05-17 | 2008-09-29 | Pfizer Products Inc., | Postupak za dobijanje 2-fenil-3-aminopiridina,njegovih supstituisanih fenil derivata, i njegovih soli |
| UA71004C2 (uk) | 1999-05-21 | 2004-11-15 | Пфайзер Продактс Інк. | Похідні 1-трифторометил-4-гідрокси-7-піперидиніламінометилхроману |
| JP2001172178A (ja) * | 1999-10-25 | 2001-06-26 | Pfizer Prod Inc | 偏頭痛治療用のｎｋ−１レセプターアンタゴニスト及びエレトリプタン |
| US20020049211A1 (en) * | 2000-09-06 | 2002-04-25 | Sobolov-Jaynes Susan Beth | Combination treatment for depression and anxiety |
| EP1192952A3 (en) * | 2000-09-28 | 2003-03-26 | Pfizer Products Inc. | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist |
| US6911544B2 (en) | 2002-10-23 | 2005-06-28 | Pfizer Inc. | Process for the preparation of (S,S)-cis-2-phenyl-3-aminopiperidine |
| BRPI0409211A (pt) | 2003-04-18 | 2006-03-28 | Lilly Co Eli | composto, composição farmacêutica, métodos para ativar receptores 5-ht1f, para inibir extravasão de proteìna neuronial, e para o tratamento ou prevenção de enxaqueca em um mamìfero, e, uso de um composto |
| CA2566920A1 (en) * | 2004-05-21 | 2005-12-01 | Pfizer Products Inc. | Metabolites of (+)-(2s, 3s)-3-(2-methoxy-5-trifluoromethoxybenzylamino)-2-phenyl-piperidine |
| RU2388751C2 (ru) | 2004-07-15 | 2010-05-10 | Амр Текнолоджи, Инк. | Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина |
| ATE550019T1 (de) | 2005-05-17 | 2012-04-15 | Merck Sharp & Dohme | Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs |
| UA95454C2 (uk) | 2005-07-15 | 2011-08-10 | Амр Текнолоджи, Інк. | Арил- і гетероарилзаміщені тетрагідробензазепіни і їх застосування для блокування зворотного захоплення норепінефрину, допаміну і серотоніну |
| KR20080048502A (ko) | 2005-09-29 | 2008-06-02 | 머크 앤드 캄파니 인코포레이티드 | 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체 |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| CA2664113C (en) | 2006-09-22 | 2013-05-28 | Merck & Co., Inc. | Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| EP2805945B1 (en) | 2007-01-10 | 2019-04-03 | MSD Italia S.r.l. | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors |
| WO2008120653A1 (ja) | 2007-04-02 | 2008-10-09 | Banyu Pharmaceutical Co., Ltd. | インドールジオン誘導体 |
| JP5501227B2 (ja) | 2007-06-27 | 2014-05-21 | メルク・シャープ・アンド・ドーム・コーポレーション | ヒストンデアセチラーゼ阻害剤としての４−カルボキシベンジルアミノ誘導体 |
| KR20100126467A (ko) | 2008-03-03 | 2010-12-01 | 타이거 파마테크 | 티로신 키나아제 억제제 |
| JP5511080B2 (ja) | 2008-03-31 | 2014-06-04 | 興和株式会社 | １，３−ジヒドロイソベンゾフラン誘導体 |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
| EP2429293B1 (en) | 2009-05-12 | 2014-10-29 | Bristol-Myers Squibb Company | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF |
| CA2760837C (en) | 2009-05-12 | 2018-04-03 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
| KR20120034644A (ko) | 2009-05-12 | 2012-04-12 | 알바니 몰레큘라 리써치, 인크. | 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도 |
| JP5099731B1 (ja) | 2009-10-14 | 2012-12-19 | メルク・シャープ・アンド・ドーム・コーポレーション | ｐ５３活性を増大する置換ピペリジン及びその使用 |
| WO2011163330A1 (en) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| EP3330377A1 (en) | 2010-08-02 | 2018-06-06 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina) |
| EP3587574B1 (en) | 2010-08-17 | 2022-03-16 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina) |
| WO2012027236A1 (en) | 2010-08-23 | 2012-03-01 | Schering Corporation | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
| EP2613782B1 (en) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
| US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| EP3327125B1 (en) | 2010-10-29 | 2020-08-05 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina) |
| EP2654748B1 (en) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
| CN103732592A (zh) | 2011-04-21 | 2014-04-16 | 默沙东公司 | 胰岛素样生长因子-1受体抑制剂 |
| US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
| WO2013165816A2 (en) | 2012-05-02 | 2013-11-07 | Merck Sharp & Dohme Corp. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
| BR112015006990A2 (pt) | 2012-09-28 | 2017-07-04 | Merck Sharp & Dohme | composto, composição farmacêutica, e, uso de pelo menos um composto |
| JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
| PT2925888T (pt) | 2012-11-28 | 2017-12-13 | Merck Sharp & Dohme | Composições e métodos para tratamento do cancro |
| CA2895504A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
| US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| WO2018071283A1 (en) | 2016-10-12 | 2018-04-19 | Merck Sharp & Dohme Corp. | Kdm5 inhibitors |
| EP3706742B1 (en) | 2017-11-08 | 2023-03-15 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5232929A (en) * | 1990-11-28 | 1993-08-03 | Pfizer Inc. | 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use |
| US5364943A (en) * | 1991-11-27 | 1994-11-15 | Pfizer Inc. | Preparation of substituted piperidines |
| CZ293955B6 (cs) * | 1991-03-26 | 2004-08-18 | Pfizeráinc | Postup přípravy substituovaných piperidinů |
| UA39168C2 (uk) * | 1991-06-20 | 2001-06-15 | Пфайзер, Інк. | Фторалкоксифенільні похідні піперидину або хінуклідину, що є антагоністами речовини p і фармацевтична композиція на їх основі |
| US5340826A (en) * | 1993-02-04 | 1994-08-23 | Pfizer Inc. | Pharmaceutical agents for treatment of urinary incontinence |
| US5393762A (en) * | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
| EP0653208A3 (en) * | 1993-11-17 | 1995-10-11 | Pfizer | Substance P antagonists for the treatment or prevention of sunburn. |
| EP0655246A1 (en) * | 1993-11-30 | 1995-05-31 | Pfizer Inc. | Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria |
| EP0780375B1 (en) * | 1995-12-21 | 2002-09-11 | Pfizer Inc. | 3-((5-substituted benzyl)amino)-2-phenylpiperidines as substance p antagonists |
| US5990125A (en) | 1996-01-19 | 1999-11-23 | Pfizer Inc. | NK-1 receptor antagonists for the treatment of cancer |
-
1996
- 1996-06-04 TW TW085106675A patent/TW340842B/zh active
- 1996-06-10 CA CA002227814A patent/CA2227814C/en not_active Expired - Fee Related
- 1996-06-10 EP EP01108350A patent/EP1114817B1/en not_active Expired - Lifetime
- 1996-06-10 CZ CZ0052198A patent/CZ297543B6/cs not_active IP Right Cessation
- 1996-06-10 EP EP96914375A patent/EP0861235B1/en not_active Expired - Lifetime
- 1996-06-10 SK SK207-98A patent/SK282925B6/sk not_active IP Right Cessation
- 1996-06-10 DE DE69616817T patent/DE69616817T2/de not_active Expired - Fee Related
- 1996-06-10 ES ES96914375T patent/ES2163017T3/es not_active Expired - Lifetime
- 1996-06-10 CN CNB961965037A patent/CN1153764C/zh not_active Expired - Fee Related
- 1996-06-10 WO PCT/IB1996/000572 patent/WO1997008144A1/en active IP Right Grant
- 1996-06-10 HU HU9901159A patent/HU225480B1/hu not_active IP Right Cessation
- 1996-06-10 SI SI9630670T patent/SI1114817T1/xx unknown
- 1996-06-10 ES ES01108350T patent/ES2211684T3/es not_active Expired - Lifetime
- 1996-06-10 UA UA98020924A patent/UA48981C2/uk unknown
- 1996-06-10 DK DK96914375T patent/DK0861235T3/da active
- 1996-06-10 PT PT96914375T patent/PT861235E/pt unknown
- 1996-06-10 AT AT01108350T patent/ATE258166T1/de not_active IP Right Cessation
- 1996-06-10 BR BR9609989A patent/BR9609989A/pt not_active Application Discontinuation
- 1996-06-10 KR KR1019980701310A patent/KR100288673B1/ko not_active IP Right Cessation
- 1996-06-10 TR TR1998/00300T patent/TR199800300T1/xx unknown
- 1996-06-10 RU RU98102959/04A patent/RU2152930C2/ru not_active IP Right Cessation
- 1996-06-10 NZ NZ308207A patent/NZ308207A/en unknown
- 1996-06-10 PL PL96325332A patent/PL186773B1/pl not_active IP Right Cessation
- 1996-06-10 SI SI9630374T patent/SI0861235T1/xx unknown
- 1996-06-10 TN TNTNSN96107A patent/TNSN96107A1/fr unknown
- 1996-06-10 DK DK01108350T patent/DK1114817T3/da active
- 1996-06-10 RO RO98-00334A patent/RO119299B1/ro unknown
- 1996-06-10 JP JP09510015A patent/JP3084069B2/ja not_active Expired - Fee Related
- 1996-06-10 AT AT96914375T patent/ATE208377T1/de not_active IP Right Cessation
- 1996-06-10 AU AU57769/96A patent/AU702698B2/en not_active Ceased
- 1996-06-10 DE DE69631390T patent/DE69631390T2/de not_active Expired - Fee Related
- 1996-06-10 MX MX9801467A patent/MX9801467A/es active IP Right Grant
- 1996-06-10 PT PT01108350T patent/PT1114817E/pt unknown
- 1996-08-15 IL IL11907896A patent/IL119078A/xx not_active IP Right Cessation
- 1996-08-20 AR ARP960104045A patent/AR006305A1/es active IP Right Grant
- 1996-08-21 PE PE2001000276A patent/PE20010700A1/es not_active Application Discontinuation
- 1996-08-21 DZ DZ960130A patent/DZ2086A1/fr active
- 1996-08-21 PE PE1996000625A patent/PE1398A1/es not_active Application Discontinuation
- 1996-08-22 HR HR960386A patent/HRP960386B1/xx not_active IP Right Cessation
- 1996-08-23 YU YU47896A patent/YU49122B/sh unknown
- 1996-08-23 MY MYPI96003496A patent/MY114800A/en unknown
- 1996-08-23 MA MA24339A patent/MA23961A1/fr unknown
- 1996-08-24 AP APAP/P/1996/000850A patent/AP643A/en active
- 1996-08-26 CO CO96045248A patent/CO4480738A1/es unknown
-
1997
- 1997-12-30 IS IS4644A patent/IS1947B/is unknown
-
1998
- 1998-02-23 OA OA9800023A patent/OA10666A/en unknown
- 1998-02-23 NO NO19980751A patent/NO310720B1/no unknown
- 1998-02-27 BG BG102288A patent/BG64126B1/bg unknown
- 1998-12-30 HK HK98119203A patent/HK1014935A1/xx not_active IP Right Cessation
-
2000
- 2000-05-01 US US09/564,398 patent/US6506775B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20010700A1 (es) | Compuestos de bencilaminopiperidina sustituidos | |
| MX9202449A (es) | 3-aminoquinuclidinas substituidas. | |
| ITMI912212A1 (it) | Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica | |
| IL96891A0 (en) | Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them | |
| NZ189418A (en) | Propanolamine and morpholine derivatives pharmaceutical compositions | |
| SE9604786D0 (sv) | New compounds | |
| DK0392959T3 (da) | Anvendelse af Sertindole til behandling af skizofreni | |
| SE8804629D0 (sv) | New therapeutically active compounds | |
| ES2180580T3 (es) | Compuestos de oxazolilo sustituidos para el tratamiento de la inflamacion. | |
| FI873631A (fi) | --alkyl-4-amino-3-kinolinmetanoler och 1-(4-aralkylamino-3-kinolinyl)alkanoler, foerfarande foer deras framstaellning och deras anvaendning som laekemedel. | |
| ATE309782T1 (de) | Zusammensetzung zur narbenbehandlung enthaltend eine silikonmischung | |
| FR2711140B1 (fr) | 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant. | |
| PH27257A (en) | Therapeutically active chloro substituted benzimidazole | |
| HUP9904073A2 (hu) | Bizmutot és nemszteroid gyulladásgátló hatóanyagot tartalmazó készítmények gasztrointesztinális rendellenességek kezelésére | |
| PT770384E (pt) | Composicoes farmaceuticas solidas anidras para utilizacao vaginal | |
| BR9503572A (pt) | Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença | |
| ES2177024T3 (es) | Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer. | |
| GR3024058T3 (en) | Pharmaceutical compositions containing 5-difluoromethoxy-2- (3,4-dimethoxy-2-pyridyl) methylsulfinyl] benzimidazole and an anti-helicobacter agent for the treatment of gastrointestinal disorders | |
| DE69227609D1 (de) | Indolderivate und ihre Verwendung | |
| ES511730A0 (es) | "un procedimiento para la preparacion de oxaprocin calcico". | |
| DE2966809D1 (en) | 3,4-diaza-bicyclo(4.1.0)hepten-2-ones-5, process for their preparation and therapeutical compositions containing them | |
| DE60309736D1 (de) | Halogeniertes hydantoin und paraffinwachs enthaltende biozide zusammensetzung | |
| ATE16382T1 (de) | Substituierte 1-oxo-2-phenyl-2-(2alkylaminoethyl)-1,2,3,4-tetrahydronaphthaline, ihre herstellung und verwendung. | |
| PT688565E (pt) | Comprimido capsula ou granulo compreendendo desogestrel | |
| NO840732L (no) | Analogifremgangsmaate for fremstilling av den terapeutisk aktive forbindelse n-(3-trifluormetylfenyl)-n`-propargylpiperazin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |